NCT02411019View on ClinicalTrials.gov

Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation

UnknownOBSERVATIONAL
Enrollment

67

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Cervical Intraepithelial Neoplasia 3
Interventions
BIOLOGICAL

GX-188E

In phase II study, 72 patients were assigned to two dose groups (1mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.

Trial Locations (1)

152-703

Korea University Guro Hospital, Seoul

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT02411019 - Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation | Biotech Hunter | Biotech Hunter